Cost utility of drugs for multiple sclerosis. Analysis goes too far. Payne N. Cost utility of drugs for multiple sclerosis. Methods used don't calculate true benefit. Systematic review places study in contrast.
Costs outweigh benefits of interferon in multiple sclerosis.
Population based cost utility study of interferon beta-1b in secondary progressive multiple sclerosis. Population based cost utility study of interferon beta-1b in secondary progressive multiple sclerosis.